• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改良 Delphi 法-panel 共识推荐的再生障碍性贫血严重程度的管理建议。

Modified Delphi panel consensus recommendations for management of severe aplastic anemia.

机构信息

Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

出版信息

Blood Adv. 2024 Aug 13;8(15):3946-3960. doi: 10.1182/bloodadvances.2023011642.

DOI:10.1182/bloodadvances.2023011642
PMID:38669341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11331724/
Abstract

Severe aplastic anemia (SAA) is a rare hematologic condition for which there is no clear management algorithm. A panel of 11 experts on adult and pediatric aplastic anemia was assembled and, using the RAND/University of California, Los Angeles modified Delphi panel method, evaluated >600 varying patient care scenarios to develop clinical recommendations for the initial and subsequent management of patients of all ages with SAA. Here, we present the panel's recommendations to rule out inherited bone marrow failure syndromes, on supportive care before and during first-line therapy, and on first-line (initial management) and second-line (subsequent management) therapy of acquired SAA, focusing on when transplant vs medical therapy is most appropriate. These recommendations represent the consensus of 11 experts informed by published literature and experience. They are intended only as general guidance for experienced clinicians who treat patients with SAA and are in no way intended to supersede individual physician and patient decision making. Current and future research should validate this consensus using clinical data. Once validated, we hope these expert panel recommendations will improve outcomes for patients with SAA.

摘要

严重再生障碍性贫血(SAA)是一种罕见的血液学疾病,目前尚无明确的治疗方案。我们组建了一个由 11 名成人和儿科再生障碍性贫血专家组成的专家组,采用 RAND/加州大学洛杉矶分校改良 Delphi 专家小组方法,对 600 多种不同的患者护理方案进行了评估,为所有年龄段 SAA 患者的初始和后续治疗制定了临床推荐意见。在这里,我们介绍专家组关于排除遗传性骨髓衰竭综合征的建议、一线治疗前和治疗期间的支持性护理、以及获得性 SAA 的一线(初始治疗)和二线(后续治疗)治疗的建议,重点讨论何时进行移植与药物治疗最恰当。这些建议是由专家组根据已发表的文献和经验达成的共识,仅供有经验的治疗 SAA 患者的临床医生参考,绝不能替代医生和患者的个体决策。当前和未来的研究应使用临床数据验证这一共识。一旦得到验证,我们希望这些专家组的推荐意见能够改善 SAA 患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d6/11331724/e956e3ca269a/BLOODA_ADV-2023-011642-gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d6/11331724/6502e45d3776/BLOODA_ADV-2023-011642-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d6/11331724/9724a7b7ebbd/BLOODA_ADV-2023-011642-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d6/11331724/a67c3f427051/BLOODA_ADV-2023-011642-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d6/11331724/caa7bf299a0b/BLOODA_ADV-2023-011642-gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d6/11331724/e956e3ca269a/BLOODA_ADV-2023-011642-gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d6/11331724/6502e45d3776/BLOODA_ADV-2023-011642-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d6/11331724/9724a7b7ebbd/BLOODA_ADV-2023-011642-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d6/11331724/a67c3f427051/BLOODA_ADV-2023-011642-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d6/11331724/caa7bf299a0b/BLOODA_ADV-2023-011642-gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d6/11331724/e956e3ca269a/BLOODA_ADV-2023-011642-gr4.jpg

相似文献

1
Modified Delphi panel consensus recommendations for management of severe aplastic anemia.改良 Delphi 法-panel 共识推荐的再生障碍性贫血严重程度的管理建议。
Blood Adv. 2024 Aug 13;8(15):3946-3960. doi: 10.1182/bloodadvances.2023011642.
2
Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP).儿童获得性再生障碍性贫血的诊断与管理。意大利儿科血液肿瘤协会(AIEOP)骨髓衰竭研究组指南。
Blood Cells Mol Dis. 2015 Jun;55(1):40-7. doi: 10.1016/j.bcmd.2015.03.007. Epub 2015 Mar 31.
3
Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.镰状细胞病(SCD)患者接受crizanlizumab 治疗时输注相关反应(IRR)管理的专家共识:RAND/UCLA 改良 Delphi 小组。
Ann Hematol. 2024 Jun;103(6):1909-1917. doi: 10.1007/s00277-024-05736-6. Epub 2024 Apr 20.
4
Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations.儿童新诊断重型再生障碍性贫血的治疗:循证推荐。
Pediatr Blood Cancer. 2024 Aug;71(8):e31070. doi: 10.1002/pbc.31070. Epub 2024 May 16.
5
A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune-suppressive therapy for newly diagnosed severe aplastic anemia: A joint pilot trial of the North American Pediatric Aplastic Anemia Consortium and the Pediatric Transplantation and Cellular Therapy Consortium.一项评估在新诊断的严重再生障碍性贫血患儿和年轻成人患者中进行随机分组,比较匹配无关供者骨髓移植与免疫抑制治疗可行性的研究:北美儿科再生障碍性贫血联合会与儿科移植和细胞治疗联合会的联合试点试验。
Pediatr Blood Cancer. 2020 Oct;67(10):e28444. doi: 10.1002/pbc.28444. Epub 2020 Aug 9.
6
Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT.遗传性骨髓衰竭综合征造血干细胞移植后的迟发效应筛查指南:第二届儿科血液与骨髓移植联合会国际儿科造血干细胞移植后迟发效应会议的共识声明
Biol Blood Marrow Transplant. 2017 Sep;23(9):1422-1428. doi: 10.1016/j.bbmt.2017.05.022. Epub 2017 May 19.
7
Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP).儿童获得性再生障碍性贫血的诊断和治疗。意大利儿科血液肿瘤学会骨髓衰竭研究组(AIEOP)指南。
Blood Cells Mol Dis. 2024 Sep;108:102860. doi: 10.1016/j.bcmd.2024.102860. Epub 2024 May 29.
8
Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation.遗传性骨髓衰竭综合征造血干细胞移植后远期效应的当前认知及未来研究重点:第二届儿科血液与骨髓移植国际联合会儿科造血干细胞移植后远期效应国际会议共识声明
Biol Blood Marrow Transplant. 2017 May;23(5):726-735. doi: 10.1016/j.bbmt.2017.01.075. Epub 2017 Jan 20.
9
How I treat acquired aplastic anemia.我如何治疗获得性再生障碍性贫血。
Blood. 2012 Aug 9;120(6):1185-96. doi: 10.1182/blood-2011-12-274019. Epub 2012 Apr 19.
10
Diagnosis and Management of Acquired Aplastic Anemia: Consensus Statement of Indian Academy of Pediatrics.获得性再生障碍性贫血的诊断和管理:印度儿科学会的共识声明。
Indian Pediatr. 2022 Jun 15;59(6):467-475. Epub 2022 Feb 1.

引用本文的文献

1
Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations.造血细胞移植和嵌合抗原受体T细胞疗法治疗血液系统疾病、实体瘤及免疫紊乱的适应证:2025年欧洲血液与骨髓移植学会实践建议
Bone Marrow Transplant. 2025 Sep 9. doi: 10.1038/s41409-025-02701-3.
2
A Multicenter Retrospective Study Comparing Immunosuppressive Therapy Combined with Eltrombopag to Immunosuppressive Therapy Alone as Frontline Treatment for Pediatric Severe Aplastic Anemia.一项多中心回顾性研究:比较免疫抑制疗法联合艾曲泊帕与单纯免疫抑制疗法作为儿童重型再生障碍性贫血一线治疗方案的疗效
Turk J Haematol. 2025 Aug 29;42(3):213-222. doi: 10.4274/tjh.galenos.2025.2025.0245. Epub 2025 Aug 11.
3

本文引用的文献

1
Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study.罗米司亭治疗难治性再生障碍性贫血的长期疗效和安全性:一项2/3期研究的随访
Blood Adv. 2024 Mar 26;8(6):1415-1419. doi: 10.1182/bloodadvances.2023010959.
2
HLA Class I Allele Loss and Bone Marrow Transplantation Outcomes in Immune Aplastic Anemia.HLA Ⅰ类等位基因缺失与再生障碍性贫血骨髓移植结局的关系。
Transplant Cell Ther. 2024 Mar;30(3):281.e1-281.e13. doi: 10.1016/j.jtct.2023.11.013. Epub 2023 Nov 14.
3
Single-cell RNA Sequencing Reveals Novel Cellular Factors for Response to Immunosuppressive Therapy in Aplastic Anemia.
Successful third haploidentical hematopoietic stem cell transplantation after two graft failures in a pediatric patient with severe aplastic anemia: a case report with five-year follow-up.一名重症再生障碍性贫血患儿在两次移植失败后成功进行了第三次单倍体相合造血干细胞移植:一项五年随访的病例报告
Front Immunol. 2025 Jul 9;16:1607926. doi: 10.3389/fimmu.2025.1607926. eCollection 2025.
4
Towards graft--host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia.为获得性再生障碍性贫血患者构建无移植物抗宿主病的替代供体移植平台。
Haematologica. 2025 Aug 1;110(8):1693-1701. doi: 10.3324/haematol.2024.286544. Epub 2025 May 29.
5
Severe Aplastic Anemia Complicated with Fatal Invasive Fungal Infections in a Young Patient Harboring Perforin Gene Polymorphisms.一名携带穿孔素基因多态性的年轻患者出现严重再生障碍性贫血并伴有致命性侵袭性真菌感染。
Hematol Rep. 2025 May 6;17(3):25. doi: 10.3390/hematolrep17030025.
6
Protective factors, management and prognosis of mixed chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia in children.儿童重型再生障碍性贫血异基因造血干细胞移植后混合嵌合体的保护因素、管理及预后
Bone Marrow Transplant. 2025 Apr 6. doi: 10.1038/s41409-025-02577-3.
7
Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database.美国获得性再生障碍性贫血患者的初始管理:来自一个大型全国索赔数据库的结果。
Ann Hematol. 2025 Apr;104(4):2507-2515. doi: 10.1007/s00277-025-06307-z. Epub 2025 Mar 19.
8
Consensus recommendations for severe aplastic anemia.重型再生障碍性贫血的共识性推荐意见。
Blood Adv. 2024 Nov 12;8(21):5719-5720. doi: 10.1182/bloodadvances.2024013529.
单细胞RNA测序揭示再生障碍性贫血中对免疫抑制治疗反应的新型细胞因子。
Hemasphere. 2023 Oct 27;7(11):e977. doi: 10.1097/HS9.0000000000000977. eCollection 2023 Nov.
4
Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China.艾曲泊帕与阿伐曲泊帕治疗难治性/复发性再生障碍性贫血的比较:一项中国单中心回顾性研究
Ther Adv Hematol. 2023 Sep 14;14:20406207231191310. doi: 10.1177/20406207231191310. eCollection 2023.
5
Uniform conditioning regardless of donor in bone marrow transplantation for severe aplastic anemia.严重再生障碍性贫血骨髓移植中不考虑供体的统一预处理
Haematologica. 2024 Feb 1;109(2):657-660. doi: 10.3324/haematol.2023.284022.
6
Haploidentical Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acquired Hypocellular Bone Marrow Failure.单倍体相合造血干细胞移植治疗小儿获得性低细胞性骨髓衰竭
Transplant Cell Ther. 2023 Oct;29(10):621.e1-621.e6. doi: 10.1016/j.jtct.2023.07.011. Epub 2023 Jul 15.
7
Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial.阿伐曲泊帕,一种有前途的新型血小板生成素受体激动剂,用于治疗难治/复发/不耐受的非重型再生障碍性贫血:一项 2 期单臂临床试验。
Ann Med. 2023 Dec;55(1):2224044. doi: 10.1080/07853890.2023.2224044.
8
System-level immune monitoring reveals new pathophysiological features in hepatitis-associated aplastic anemia.系统水平的免疫监测揭示了肝炎相关性再生障碍性贫血新的病理生理特征。
Blood Adv. 2023 Aug 8;7(15):4039-4045. doi: 10.1182/bloodadvances.2022008224.
9
Prospective Study of a Modified Post-Transplantation Cyclophosphamide Regimen for Severe Aplastic Anemia Patients with HLA-Haploidentical Transplantation.HLA 单倍体相合移植治疗重型再生障碍性贫血患者的改良移植后环磷酰胺方案的前瞻性研究。
Transplant Cell Ther. 2023 Jul;29(7):463.e1-463.e7. doi: 10.1016/j.jtct.2023.04.015. Epub 2023 Apr 24.
10
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia.异基因造血干细胞移植联合移植后环磷酰胺治疗获得性重型再生障碍性贫血。
Blood. 2023 Jun 22;141(25):3031-3038. doi: 10.1182/blood.2023020435.